5Schulman KA, Linas B P. Pharmacoeconomics : State of the art in 1997. AmmuRev- Pubic Health , 1997; 18:529
6Einarson TR. Pharmacoeconomic applications of meta- analysis for singlegroups using antifungal onychomycosis lacquers as an example. Clin. Ther, 1997;19(3): 559
7Jaeschke R, Guyatt G, Shannon H, et al. Basis statistics for clinicians: assessing the effects of treatment measures of association. Can Med Assoc J, 1995;152:351 ~ 357
8Luce BR, Elichauser A. Estimating costs in the economic evalution of medical technologies. Int. J Technol Assess Health Care . 1990, 6:57
9Menon D , Scheubert F, Torrance G.W. Canada new guildlines for economics evaluation of pharmaceceticals. Medical Care. 1996; 12 (supplement): 77
10Gmitchell A. Update and evaluation of Australian guidelines/ government perspective.Medical Care. 1996; 12 (supplement): 216